Thomas et al. reported that administration of IFN-α and IFN-λ may similarly ameliorate ICS impairment of lung influenza virus control in mice16, although inhaled IFN-β is the therapy that is in clinical development and therefore of greatest current interest. Here, IFNB1 is linked to medical procedure.